1. Is molecular targeted therapy suitable for patients with breast cancer brain metastasis? Although trastuzumab can significantly reduce the recurrence risk of early breast cancer with Her2 overexpression, it cannot pass the blood-brain barrier and has limited therapeutic value for breast cancer brain metastasis. Lapatinib is a small molecule targeting Her1 and Her2, which can pass the blood-brain barrier, but its efficacy in patients with brain metastasis of breast cancer has yet to be confirmed. 2.Does endocrine therapy have a role in patients with breast cancer brain metastases? At present, endocrine therapy is not recommended as the first-line treatment for breast cancer brain metastasis. Endocrine therapy can be tried for receptor-positive breast cancer brain metastasis patients with milder symptoms. However, although tamoxifen can cross the blood-brain barrier, most patients with breast cancer brain metastases are advanced and have developed resistance to tamoxifen in previous treatments, so the therapeutic effect is quite limited.